There are situations when you need to evaluate MHC-binding of peptides not just on its own but how a peptide or peptide-mimetic competes with a known control peptide for binding.
As an extension to our regular ProImmune REVEAL® MHC-peptide binding and rate assays we are now also offering MHC-peptide competition binding assays.
These new assays are currently available for the following HLA-DR supertypes:
HLA-DRB1*01:01, *03:01, *04:01, *04:05, *07:01, *09:01, *11:01, *15:01.
Like our other specialist assays our competition assays turn around rapidly in only a few weeks.
Figure 1. Competition assay principle: A labelled control peptide is bound to the MHC-complex, giving a high baseline signal in an immunoassay. As the peptide is competed away with unlabelled competitor peptide the signal reduces at increasing concentration of competitor peptide. The control peptide is usually a well known HLA-Class II restricted immunodominant T cell epitope which is further known to be restricted to the HLA-DR supertype of interest.
Control peptides can be chosen depending on the assay objective
Test peptide or compounds provided by customer or made by ProImmune
The concentration range can be varied to suit the specific project objective
Mixtures of peptides as well as mono-disperse peptides can be tested
Jansson L., Wraith D., et al. (2018). “Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice” Endocrinology, Volume 159, Issue 9, Sep., pp 3446–3457 https://doi.org/10.1210/en.2018-00306
See ProImmune REVEAL® and ProVE customer publications
